336 related articles for article (PubMed ID: 15562141)
21. The effects of glucagon-like peptide-1 on the beta cell.
Vilsbøll T
Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():11-8. PubMed ID: 19878257
[TBL] [Abstract][Full Text] [Related]
22. Incretin physiology and its role in type 2 diabetes mellitus.
Svec F
J Am Osteopath Assoc; 2010 Jul; 110(7 Suppl 7):eS20-4. PubMed ID: 20644202
[TBL] [Abstract][Full Text] [Related]
23. Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists.
Hansen KB; Knop FK; Holst JJ; Vilsbøll T
Int J Clin Pract; 2009 Aug; 63(8):1154-60. PubMed ID: 19624785
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
Gallwitz B
Diabetes Technol Ther; 2005 Aug; 7(4):651-7. PubMed ID: 16120042
[TBL] [Abstract][Full Text] [Related]
25. Evaluating the long-term cost-effectiveness of liraglutide versus exenatide BID in patients with type 2 diabetes who fail to improve with oral antidiabetic agents.
Valentine WJ; Palmer AJ; Lammert M; Langer J; Brändle M
Clin Ther; 2011 Nov; 33(11):1698-712. PubMed ID: 22018679
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
Nauck M
Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
[TBL] [Abstract][Full Text] [Related]
27. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
28. Exenatide: a new option for the treatment of type 2 diabetes.
Yoo BK; Triller DM; Yoo DJ
Ann Pharmacother; 2006 Oct; 40(10):1777-84. PubMed ID: 16985091
[TBL] [Abstract][Full Text] [Related]
29. Exenatide: a novel approach for treatment of type 2 diabetes.
Mikhail N
South Med J; 2006 Nov; 99(11):1271-9. PubMed ID: 17195423
[TBL] [Abstract][Full Text] [Related]
30. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
Diamant M; Bunck MC; Heine RJ
Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
[TBL] [Abstract][Full Text] [Related]
31. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
Rachman J; Barrow BA; Levy JC; Turner RC
Diabetologia; 1997 Feb; 40(2):205-11. PubMed ID: 9049482
[TBL] [Abstract][Full Text] [Related]
32. Emerging GLP-1 receptor agonists.
Lund A; Knop FK; Vilsbøll T
Expert Opin Emerg Drugs; 2011 Dec; 16(4):607-18. PubMed ID: 21905764
[TBL] [Abstract][Full Text] [Related]
33. Incretins and other peptides in the treatment of diabetes.
Todd JF; Bloom SR
Diabet Med; 2007 Mar; 24(3):223-32. PubMed ID: 17263764
[TBL] [Abstract][Full Text] [Related]
34. Exenatide: its position in the treatment of type 2 diabetes.
Guerci B; Martin CS
Ann Endocrinol (Paris); 2008 Jun; 69(3):201-9. PubMed ID: 18533126
[TBL] [Abstract][Full Text] [Related]
35. Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.
Kissow H; Hartmann B; Holst JJ; Viby NE; Hansen LS; Rosenkilde MM; Hare KJ; Poulsen SS
Regul Pept; 2012 Nov; 179(1-3):91-100. PubMed ID: 22989472
[TBL] [Abstract][Full Text] [Related]
36. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
37. Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus.
Baron AD; Kim D; Weyer C
Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):63-82. PubMed ID: 12477297
[TBL] [Abstract][Full Text] [Related]
38. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
Blonde L; Montanya E
Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
[TBL] [Abstract][Full Text] [Related]
39. Proglucagon-derived peptides: mechanisms of action and therapeutic potential.
Sinclair EM; Drucker DJ
Physiology (Bethesda); 2005 Oct; 20():357-65. PubMed ID: 16174875
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of liraglutide, a once-daily human glucagon-like peptide-1 analog, in healthy volunteers and subjects with type 2 diabetes, and comparison to twice-daily exenatide.
Watson E; Jonker DM; Jacobsen LV; Ingwersen SH
J Clin Pharmacol; 2010 Aug; 50(8):886-94. PubMed ID: 20133507
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
